Current Trends and Glimpse for All Pharma Global Regulatory Agencies Requirements of Nitrosamine and NDSRIs Impurities in Pharmaceuticals

Journal Title: Der Pharma Chemica - Year 2024, Vol 16, Issue 2

Abstract

The USFDA and EMEA announced in July 2018 that N-Nitroso Dimethylamine and N-N-NDMA are concentrated on pharmaceutical medicinal products and specifically used in case of SARTANS that are used in the treatment of hypertension and angiotensin II receptor blockers, bringing the seriousness of nitrosamine presence to light. Subsequently, the diabetes medication pioglitazone and the histamine-2 blocker ranitidine were added to the list. Nitrosamines are created when amines, secondary amide carbamates and urea derivatives react with nitrates and nitrogenous agents. Nitrogen is at an oxidation state of +3. Pharmaceutical product degradation, catalysts, solvents, chemical reagents, cross-contamination, the manufacturing process and raw material contamination are some of the causes of nitrosamine presence in pharmaceutical products. Nitrosamine Impurity is detected using technologies such as gas chromatography, mass spectroscopy and light chromatography mass spectroscopy. According to ICH recommendations, N-nitrosamines are classified as a "cohort of concern" because they may be carcinogen and mutagen. The natural world. Class 2A human substances include N-nitroso dimethylamine and N-nitroso diethylamine. The possibility of N-nitrosamine contaminants in pharmaceutical goods poses a problem for the control of medical product quality. N-nitrosamines are regarded as substances of concern since many of the structurally straightforward molecules in this class have strong carcinogenic properties.

Authors and Affiliations

Rashid Azeez, Kalyani Bhor and Vinod A Bairagi

Keywords

Related Articles

Current Trends for Regulatory Requirements of Elemental Impurity in Drug Substance for Regulatory Market

The presence of elemental impurities in drug substances has gained increasing attention in the pharmaceutical industry due to their potential impact on product safety and efficacy. Regulatory agencies worldwide have esta...

Protein Assembly: An Understanding and Clarification

Alzheimer's disease is characterized by the accumulation of mis folded proteins that form fibrillary amyloid deposits in specific regions of the central nervous system. This leads to memory loss, changes in personality,...

A Catalyst Free Simple and Efficient One Pot Synthesis of N-benzyloxazolidinone Derivatives

An efficient and catalyst free one pot synthesis of N-benzyloxazolidinone derivatives is developed by reaction of N-benzyl-β-amino alcohol derivatives and N, N-Carbonyldiimidazole (CDI) in DMSO. A range of novel N-benzyl...

Requalification of Friability Testing Apparatus

Re-qualification as a part of validation is the task performed to identify or check that utilities, equipment and ancillary systems can operate within limits for their intended use. Equipment qualification is a key eleme...

Exploring the Potential Flavonoids as an Anti-Rheumatoid Arthritis Agent: An In silico Studies

Rheumatoid arthritis is an autoimmune disease which causes systemic complications, disability and even death. Its pathophysiology involves chronic inflammation of synovial membrane. New molecules in the biologic pathway...

Download PDF file
  • EP ID EP742508
  • DOI 10.4172/0975- 413X.16.2.263-273
  • Views 75
  • Downloads 0

How To Cite

Rashid Azeez, Kalyani Bhor and Vinod A Bairagi (2024). Current Trends and Glimpse for All Pharma Global Regulatory Agencies Requirements of Nitrosamine and NDSRIs Impurities in Pharmaceuticals. Der Pharma Chemica, 16(2), -. https://europub.co.uk/articles/-A-742508